TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ATAI Life Sciences ( (ATAI) ) has provided an announcement.
On December 5, 2025, Atai Beckley N.V. filed a prospectus supplement with the SEC regarding its common shares, which are being registered to fulfill certain contractual rights related to the acquisition of Beckley Psytech Limited. This filing is part of the company’s registration statement process and includes a legal opinion on the validity of the shares.
The most recent analyst rating on (ATAI) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.
Spark’s Take on ATAI Stock
According to Spark, TipRanks’ AI Analyst, ATAI is a Underperform.
ATAI Life Sciences’ overall stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and negative cash flows. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and oversold indicators. The negative P/E ratio further reflects the company’s financial struggles, leading to a low overall score.
To see Spark’s full report on ATAI stock, click here.
More about ATAI Life Sciences
Average Trading Volume: 5,780,412
Technical Sentiment Signal: Buy
Current Market Cap: $1.6B
For detailed information about ATAI stock, go to TipRanks’ Stock Analysis page.